176 related articles for article (PubMed ID: 38423172)
1. Exploring the multifaceted effects of Interleukin-1 in lung cancer: From tumor development to immune modulation.
Tang M; Yin Y; Wang W; Gong K; Dong J; Gao X; Li J; Fang L; Ma J; Hong Y; Li Z; Bi T; Zhang W; Liu W
Life Sci; 2024 Apr; 342():122539. PubMed ID: 38423172
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.
Castillo DR; Jeon WJ; Park D; Pham B; Yang C; Joung B; Moon JH; Lee J; Chong EG; Park K; Reeves ME; Duerksen-Hughes P; Mirshahidi HR; Mirshahidi S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511306
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
Eskandari-Malayeri F; Rezaei M
Front Immunol; 2022; 13():996145. PubMed ID: 36275750
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
5. Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins.
Nasser MW; Elbaz M; Ahirwar DK; Ganju RK
Cancer Lett; 2015 Aug; 365(1):11-22. PubMed ID: 25963887
[TBL] [Abstract][Full Text] [Related]
6. [Interleukin-34: a key molecule in the tumor microenvironment].
Kajihara N; Seino KI
Rinsho Ketsueki; 2021; 62(8):1302-1307. PubMed ID: 34497220
[TBL] [Abstract][Full Text] [Related]
7. The Microenvironment of Lung Cancer and Therapeutic Implications.
Mittal V; El Rayes T; Narula N; McGraw TE; Altorki NK; Barcellos-Hoff MH
Adv Exp Med Biol; 2016; 890():75-110. PubMed ID: 26703800
[TBL] [Abstract][Full Text] [Related]
8. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
Dzobo K
OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
[TBL] [Abstract][Full Text] [Related]
9. Chronic inflammation, cancer development and immunotherapy.
Wen Y; Zhu Y; Zhang C; Yang X; Gao Y; Li M; Yang H; Liu T; Tang H
Front Pharmacol; 2022; 13():1040163. PubMed ID: 36313280
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
Front Immunol; 2019; 10():757. PubMed ID: 31031757
[TBL] [Abstract][Full Text] [Related]
11. Effects of IFN-γ on the immunological microenvironment and TAM polarity in stage IA non-small cell lung cancer and its mechanisms.
Zhao W; Wang H; Zhang X; Zhang L; Pu W; Ma Y; Chen W
BMC Pulm Med; 2024 Jan; 24(1):46. PubMed ID: 38254043
[TBL] [Abstract][Full Text] [Related]
12. Strategy of targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling new era to cancer chemo-immunotherapy resistance.
Tajaldini M; Poorkhani A; Amiriani T; Amiriani A; Javid H; Aref P; Ahmadi F; Sadani S; Khori V
Eur J Pharmacol; 2023 Oct; 957():175991. PubMed ID: 37619785
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-1 receptor accessory protein (IL-1RAP): A magic bullet candidate for immunotherapy of human malignancies.
Zarezadeh Mehrabadi A; Shahba F; Khorramdelazad H; Aghamohammadi N; Karimi M; Bagherzadeh K; Khoshmirsafa M; Massoumi R; Falak R
Crit Rev Oncol Hematol; 2024 Jan; 193():104200. PubMed ID: 37981104
[TBL] [Abstract][Full Text] [Related]
14. Cell-mediated barriers in cancer immunosurveillance.
Rezaie J; Chodari L; Mohammadpour-Asl S; Jafari A; Niknam Z
Life Sci; 2024 Apr; 342():122528. PubMed ID: 38408406
[TBL] [Abstract][Full Text] [Related]
15. Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy.
Li T; Qiao T
Semin Cancer Biol; 2022 Nov; 86(Pt 2):117-125. PubMed ID: 36183998
[TBL] [Abstract][Full Text] [Related]
16. Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime.
Pradip D; Jennifer A; Nandini D
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502029
[TBL] [Abstract][Full Text] [Related]
17. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L
Ann Oncol; 2016 Aug; 27(8):1482-92. PubMed ID: 27069014
[TBL] [Abstract][Full Text] [Related]
18. IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment.
Yi P; Yu W; Xiong Y; Dong Y; Huang Q; Lin Y; Du Y; Hua F
Mol Cancer Ther; 2024 Feb; 23(2):148-158. PubMed ID: 37988561
[TBL] [Abstract][Full Text] [Related]
19. Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.
Bule P; Aguiar SI; Aires-Da-Silva F; Dias JNR
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575965
[TBL] [Abstract][Full Text] [Related]
20. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
